Nexthera Capital’s TG Therapeutics TGTX Stock Holding History

Nexthera Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,000	Closed	-$658K	–	66
2018 Q2	$658K	Buy	+50,000	New	+$688K	0.1%	43

Other funds holding TGTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nexthera Capital's TGTX Position: Q4 2018 in Review

Nexthera Capital sold out of TG Therapeutics (TGTX) in Q4 2018, closing a stake of 445,000 shares — an estimated $2.49M sold.

Nexthera Capital first reported a position in TGTX in Q4 2017 and held it in 3 quarters. The position peaked at $2.49M in Q3 2018. 115 funds tracked by Wall St. Rank hold TGTX as of Q4 2018.

Nexthera Capital reported no remaining TG Therapeutics position as of Q4 2018 after selling out during the quarter.
Nexthera Capital sold 445,000 TG Therapeutics shares in Q4 2018, an estimated $2.49M.
Nexthera Capital first reported a position in TG Therapeutics in Q4 2017 and held it in 3 quarters.
Nexthera Capital's TG Therapeutics position peaked at $2.49M in Q3 2018.
115 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.